Myrtucommulone

• CAT Number: I032947
• CAS Number: 54247-21-1
• Molecular Formula: C38H52O10
• Molecular Weight: 668.82
• Purity: 98%
• Synonyms: Myrtucommulone
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 5-hydroxy-2,2,6,6-tetramethyl-4-[(1R)-2-methyl-1-[2,4,6-trihydroxy-3-[(1R)-1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohexen-1-yl)-2-methylpropyl]-5-(2-methylpropanoyl)phenyl]propyl]cyclohex-4-ene-1,3-dione
• InChI: InChI=1S/C38H52O10/c1-15(2)18(22-29(43)35(7,8)33(47)36(9,10)30(22)44)20-26(40)21(28(42)24(27(20)41)25(39)17(5)6)19(16(3)4)23-31(45)37(11,12)34(48)38(13,14)32(23)46/h15-19,40-43,45H,1-14H3/t18-,19-/m1/s1
• InChIKey: BIHONVMOJSPPFL-RTBURBONSA-N
• SMILES: CC(C)[C@H](C1=C(C(=C(C(=C1O)C(=O)C(C)C)O)[C@H](C2=C(C(C(=O)C(C2=O)(C)C)(C)C)O)C(C)C)O)C3=C(C(C(=O)C(C3=O)(C)C)(C)C)O

Myrtucommulone（Cat No.:I032947）is a bioactive compound derived from the Myrtus communis plant, commonly known as the myrtle. It belongs to the family of diterpenoids and has been studied for its antimicrobial, anti-inflammatory, and antioxidant properties. Research indicates that myrtucommulone may have therapeutic potential in treating conditions associated with oxidative stress and inflammation, such as chronic inflammatory diseases and infections. It has shown promise in preclinical studies for modulating immune responses and inhibiting microbial growth. However, further research is needed to fully assess its safety, efficacy, and potential clinical applications.

Reference

1: Wiechmann K, Müller H, König S, Wielsch N, Svatoš A, Jauch J, Werz O. Mitochondrial Chaperonin HSP60 Is the Apoptosis-Related Target for Myrtucommulone. Cell Chem Biol. 2017 Apr 27. pii: S2451-9456(17)30108-3. doi: 10.1016/j.chembiol.2017.04.008. [Epub ahead of print] PubMed PMID: 28457707.
2: Liu C, Ang S, Huang XJ, Tian HY, Deng YY, Zhang DM, Wang Y, Ye WC, Wang L. Meroterpenoids with New Skeletons from Myrtus communis and Structure Revision of Myrtucommulone K. Org Lett. 2016 Aug 19;18(16):4004-7. doi: 10.1021/acs.orglett.6b01817. Epub 2016 Jul 29. PubMed PMID: 27471772.
3: Izgi K, Iskender B, Sakalar C, Arslanhan A, Yüksek EH, Hizar E, Canatan H. Effects of Epirubicin and Cisplatin against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A. Anticancer Agents Med Chem. 2016 Apr 4. [Epub ahead of print] PubMed PMID: 27039926.
4: Iskender B, Izgi K, Canatan H. Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial-mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis. Mol Cell Biochem. 2016 May;416(1-2):71-84. doi: 10.1007/s11010-016-2697-y. Epub 2016 Mar 31. PubMed PMID: 27032769.
5: Iskender B, Izgi K, Hizar E, Jauch J, Arslanhan A, Yuksek EH, Canatan H. Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling. Tumour Biol. 2016 Jun;37(6):8281-91. doi: 10.1007/s13277-015-4695-1. Epub 2015 Dec 30. PubMed PMID: 26718217.
6: Khanh PN, Duc HV, Huong TT, Son NT, Ha VT, Van DT, Tai BH, Kim JE, Jo AR, Kim YH, Cuong NM. Alkylphloroglucinol derivatives and triterpenoids with soluble epoxide hydrolase inhibitory activity from Callistemon citrinus. Fitoterapia. 2016 Mar;109:39-44. doi: 10.1016/j.fitote.2015.10.013. Epub 2015 Nov 5. PubMed PMID: 26548595.
7: Hans M, Charpentier M, Huch V, Jauch J, Bruhn T, Bringmann G, Quandt D. Stereoisomeric Composition of Natural Myrtucommulone A. J Nat Prod. 2015 Oct 23;78(10):2381-9. doi: 10.1021/acs.jnatprod.5b00358. Epub 2015 Oct 12. PubMed PMID: 26457652.
8: Ogur R. Studies with Myrtus communis L.: Anticancer properties. J Intercult Ethnopharmacol. 2014 Oct-Dec;3(4):135-7. doi: 10.5455/jice.20140803044831. Epub 2014 Aug 3. Review. PubMed PMID: 26401362; PubMed Central PMCID: PMC4576805.
9: Wiechmann K, Müller H, Fischer D, Jauch J, Werz O. The acylphloroglucinols hyperforin and myrtucommulone A cause mitochondrial dysfunctions in leukemic cells by direct interference with mitochondria. Apoptosis. 2015 Nov;20(11):1508-17. doi: 10.1007/s10495-015-1170-9. PubMed PMID: 26386573.
10: Iskender B, Izgi K, Sakalar C, Canatan H. Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway? Tumour Biol. 2016 Feb;37(2):1967-81. doi: 10.1007/s13277-015-3995-9. Epub 2015 Sep 3. PubMed PMID: 26334623.
11: Wiechmann K, Müller H, Huch V, Hartmann D, Werz O, Jauch J. Synthesis and biological evaluation of novel myrtucommulones and structural analogues that target mPGES-1 and 5-lipoxygenase. Eur J Med Chem. 2015 Aug 28;101:133-49. doi: 10.1016/j.ejmech.2015.06.001. Epub 2015 Jun 5. PubMed PMID: 26123643.
12: Iskender B, Izgi K, Karaca H, Canatan H. Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9. J Nat Med. 2015 Oct;69(4):543-54. doi: 10.1007/s11418-015-0923-7. Epub 2015 Jun 9. PubMed PMID: 26054707.
13: Izgi K, Iskender B, Jauch J, Sezen S, Cakir M, Charpentier M, Canatan H, Sakalar C. Myrtucommulone-A Induces both Extrinsic and Intrinsic Apoptotic Pathways in Cancer Cells. J Biochem Mol Toxicol. 2015 Jun 2. doi: 10.1002/jbt.21716. [Epub ahead of print] PubMed PMID: 26032814.
14: Grandjenette C, Schnekenburger M, Morceau F, Mack F, Wiechmann K, Werz O, Dicato M, Diederich M. Dual induction of mitochondrial apoptosis and senescence in chronic myelogenous leukemia by myrtucommulone A. Anticancer Agents Med Chem. 2015;15(3):363-73. PubMed PMID: 25469628.
15: Alipour G, Dashti S, Hosseinzadeh H. Review of pharmacological effects of Myrtus communis L. and its active constituents. Phytother Res. 2014 Aug;28(8):1125-36. doi: 10.1002/ptr.5122. Epub 2014 Feb 4. Review. PubMed PMID: 24497171.
16: Nicoletti R, Ferranti P, Caira S, Misso G, Castellano M, Di Lorenzo G, Caraglia M. Myrtucommulone production by a strain of Neofusicoccum australe endophytic in myrtle (Myrtus communis). World J Microbiol Biotechnol. 2014 Mar;30(3):1047-52. doi: 10.1007/s11274-013-1523-x. Epub 2013 Oct 17. PubMed PMID: 24132497.
17: Choudhary MI, Khan N, Ahmad M, Yousuf S, Fun HK, Soomro S, Asif M, Mesaik MA, Shaheen F. New inhibitors of ROS generation and T-cell proliferation from Myrtus communis. Org Lett. 2013 Apr 19;15(8):1862-5. doi: 10.1021/ol4002976. Epub 2013 Apr 3. PubMed PMID: 23550772.
18: Gerbeth K, Hüsch J, Meins J, Rossi A, Sautebin L, Wiechmann K, Werz O, Skarke C, Barrett JS, Schubert-Zsilavecz M, Abdel-Tawab M. Myrtucommulone from Myrtus communis: metabolism, permeability, and systemic exposure in rats. Planta Med. 2012 Dec;78(18):1932-8. doi: 10.1055/s-0032-1327881. Epub 2012 Nov 13. PubMed PMID: 23150076.
19: Cottiglia F, Casu L, Leonti M, Caboni P, Floris C, Busonera B, Farci P, Ouhtit A, Sanna G. Cytotoxic phloroglucinols from the leaves of Myrtus communis. J Nat Prod. 2012 Feb 24;75(2):225-9. doi: 10.1021/np2009219. Epub 2012 Jan 25. PubMed PMID: 22276775.
20: Fiorini-Puybaret C, Aries MF, Fabre B, Mamatas S, Luc J, Degouy A, Ambonati M, Mejean C, Poli F. Pharmacological properties of Myrtacine® and its potential value in acne treatment. Planta Med. 2011 Sep;77(14):1582-9. doi: 10.1055/s-0030-1270955. Epub 2011 Mar 30. Erratum in: Planta Med. 2011 Sep;77(14):E12. PubMed PMID: 21452108.